May 13, 2020 / 12:18 PM / in 15 days

BRIEF-First Patient Dosed With I-Mab's CD73 Antibody TJD5 In Phase 1/2 Clinical Trial In China For Advanced Solid Tumors

May 13 (Reuters) - I-Mab:

* FIRST PATIENT DOSED WITH I-MAB’S CD73 ANTIBODY TJD5 IN PHASE 1/2 CLINICAL TRIAL IN CHINA FOR ADVANCED SOLID TUMORS Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below